TEVA-PROPOFOL 10 MG
PROPOFOL : 10 MG · DIN 02437961 · TEVA CANADA LIMITED
Health Canada status: DORMANT
What is TEVA-PROPOFOL?
TEVA-PROPOFOL 10 MG contains PROPOFOL : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02437961, held by TEVA CANADA LIMITED, supplied as EMULSION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 25-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-PROPOFOL used for?
Induction and maintenance of general anaesthesia; conscious sedation for surgical and diagnostic procedures; sedation during intensive care in intubated, mechanically ventilated adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02437961 |
|---|---|
| Brand name | TEVA-PROPOFOL |
| Generic / active ingredient | PROPOFOL : 10 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 10 MG |
| Dosage form | EMULSION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | N01AX10 PROPOFOL |
| AHFS class | 28:04.08 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 25-Feb-2022 |
| Original market date | 2015-11-20 00:00:00 |
How is it administered?
Individually titrated. Induction (Adults <55): 2.0-2.5 mg/kg. Maintenance: 0.1-0.2 mg/kg/min. ICU Sedation: 0.005-0.050 mg/kg/min (max 4 mg/kg/h). Administer via infusion or slow injection.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Do not freeze. (Specific temperature range not in provided text).
How is it supplied?
Vials (single-use parenteral product).
Contraindications
Hypersensitivity to propofol, lipid emulsions, eggs/egg products, or soybeans/soy products; sedation of children 18 years or younger in ICU; when sedation or general anaesthesia are contraindicated.
Warnings and precautions
Must be administered by persons trained in general anaesthesia. Risk of fatal respiratory complications without airway care. Maintain strict aseptic technique (supports microbial growth).
What can be used instead?
Other Canadian products sharing ATC code N01AX10 PROPOFOL. 4 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DIPRIVAN 1% | 10 MG | EMULSION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02018950 |
| PROPOFOL INJECTION | 10 MG | EMULSION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02437643 |
| PROPOFOL INJECTION | 10 MG | EMULSION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02525879 |
| PROPOFOL INJECTION | 10 MG | EMULSION | BAXTER CORPORATION | MARKETED | DIN 02244379 |
| PROPOFOL | 10 MG | EMULSION | BAXTER CORPORATION | CANCELLED POST MARKET | DIN 02468336 |
| PROPOFOL INJECTION | 10 MG | EMULSION | STERIMAX INC | APPROVED | DIN 02559692 |
| PROPOFOL INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02236887 |
| PROPOFOL INJECTION | 10 MG | EMULSION | NOVOPHARM LIMITED | CANCELLED POST MARKET | DIN 02241504 |
| PROPOFOL INJECTION | 10 MG | EMULSION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02242973 |
| PROPOFOL-II INJECTION | 10 MG | EMULSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02376865 |
Who else supplies PROPOFOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PROPOFOL appears in 1483 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.